Home › Funds › D. E. Shaw & Co › BSX

D. E. Shaw & Co position in BSX

BOSTON SCIENTIFIC CORP · Health Care

D. E. Shaw & Co reported holding 27,267,209 shares of BSX (BOSTON SCIENTIFIC CORP) in its Q2 2026 13F filing — a position valued at US$1.16B, representing 0.61% of its reported portfolio and ranking #24 among its reported holdings. D. E. Shaw & Co has disclosed BSX holdings in 20 of the last 20 reported quarters, going back to Q3 2021.

Latest position (Q2 2026)27.27M sh
Reported value held$1.16B
Portfolio Weight0.61%
First reportedQ3 2021
Last changeAdd
Updated2026-10-05

Last updated: 2026-10-05 · Source: SEC EDGAR Form 13F-HR

How D. E. Shaw & Co's BSX position evolved

D. E. Shaw & Co first disclosed a stake in BSX in Q3 2021 at 337,953 shares (US$14.7M). The position peaked in Q1 2026 at 24,432,352 shares, worth US$1.53B. Across 20 filings, D. E. Shaw & Co increased the stake 11 time(s), trimmed it 8 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 27,267,209 shares valued at US$1.16B — an increase of 2,834,857 shares quarter over quarter.. Notable position changes include a 337% increase in Q4 2021 (shares rose 4% over the following quarter), a 358% increase in Q2 2022 (shares rose 4% over the following quarter), a 376% increase in Q1 2025 (shares rose 6% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2021 337.95K $14.66M New
Q4 2021 1.48M $62.73M Add
Q1 2022 584.22K $25.88M Reduce
Q2 2022 2.68M $99.77M Add
Q3 2022 1.82M $70.57M Reduce
Q4 2022 827.13K $38.27M Reduce
Q1 2023 471.75K $23.60M Reduce
Q2 2023 1.17M $63.06M Add
Q3 2023 1.14M $60.06M Reduce
Q4 2023 519.45K $30.03M Reduce
Q1 2024 1.40M $95.80M Add
Q2 2024 882.73K $67.98M Reduce
Q3 2024 1.82M $152.93M Add
Q4 2024 832.40K $74.35M Reduce
Q1 2025 3.96M $399.85M Add
Q2 2025 6.88M $738.78M Add
Q3 2025 8.94M $872.85M Add
Q4 2025 11.25M $1.07B Add
Q1 2026 24.43M $1.53B Add
Q2 2026 27.27M $1.16B Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BSX and 13F data

BSX (BOSTON SCIENTIFIC CORP) is a Health Care company. 19 other funds we track also report a position in BSX — the largest reported positions include Banque Cantonale Vaudoise (US$2.89B), PRIMECAP MANAGEMENT CO/CA/ (US$2.16B), Janus Henderson Group (US$1.04B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BSX

All BSX fund holders →

FAQ

How long has D. E. Shaw & Co held BSX?

D. E. Shaw & Co has disclosed BSX holdings in 20 of the last 20 reported quarters, going back to Q3 2021.

What is D. E. Shaw & Co's current position in BSX?

As of Q2 2026, D. E. Shaw & Co holds 27.27M shares of BSX (BOSTON SCIENTIFIC CORP), valued at $1.16B, representing 0.61% of its reported portfolio and ranking #24.

Has D. E. Shaw & Co been buying or selling BSX?

In the latest 13F filing (Q2 2026), D. E. Shaw & Co increased its position in BSX. The position peaked in Q1 2026 at 24.43M shares.

Which other funds hold BSX?

Other major institutional holders of BSX include Banque Cantonale Vaudoise, PRIMECAP MANAGEMENT CO/CA/, Janus Henderson Group, among 19 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.